Literature DB >> 19641890

Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-kappaB-inducing kinase-specific siRNA using liver-targeting liposomes.

Hyun-Ah Cho1, In-Sung Park, Tae-Woo Kim, Yu-Kyoung Oh, Ki-Sook Yang, Jin-Seok Kim.   

Abstract

Hepatitis B virus triggers an increase of NF-kappaB inducing kinase (NIK)-dependent NF-kappaB activation, followed by the promotion of hepatocellular carcinoma (HCC). Here, we examined the inhibitory effect of NIK-specific siRNA on NF-kappaB signaling and HCC. The results of this study indicated that these siRNAs suppressed HBV-derived HCC by regulating NIK activation. To exert a protective effect from degradation enzyme, cationic liposomes were contrived and modified to contain beta-sitosterol glucoside to target the asialoglycoprotein receptors in liver cancer cells. The cationic dimyristoyl diacyltrimethylammonium propane liposomes were prepared by a reverse-phase evaporation method with slight modification. beta-Sitosterol glucoside was added to the lipid mixture at the beginning of the liposome preparation for the purpose of liver targeting. These liposomes assisted the delivery of the siRNA to specific cells and protected it from various lyases, followed by the ultimate suppression of HCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19641890     DOI: 10.1007/s12272-009-1714-z

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  7 in total

Review 1.  Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection.

Authors:  María L Cuestas; Verónica L Mathet; José R Oubiña; Alejandro Sosnik
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

2.  Co-culture of hepatoma cells with hepatocytic precursor (stem-like) cells inhibits tumor cell growth and invasion by downregulating Akt/NF-κB expression.

Authors:  Cheng-Jun Sui; Miao Xu; Wei-Qing Li; Jia-Mei Yang; Hong-Zhu Yan; Hui-Min Liu; Chun-Yan Xia; Hong-Yu Yu
Journal:  Oncol Lett       Date:  2016-09-13       Impact factor: 2.967

Review 3.  Progress and Prospects of Non-Canonical NF-κB Signaling Pathway in the Regulation of Liver Diseases.

Authors:  Li Tao; Xiaomeng Ren; Wenhui Zhai; Zheng Chen
Journal:  Molecules       Date:  2022-07-02       Impact factor: 4.927

4.  Chemosensitization of HepG2 cells by suppression of NF-κB/p65 gene transcription with specific-siRNA.

Authors:  Yun Shi; Si-Ye Wang; Min Yao; Wen-Li Sai; Wei Wu; Jun-Ling Yang; Yin Cai; Wen-Jie Zheng; Deng-Fu Yao
Journal:  World J Gastroenterol       Date:  2015-12-07       Impact factor: 5.742

Review 5.  Noncanonical NF-κB Signaling Pathway in Liver Diseases.

Authors:  Qianhui Chen; Xinyu Lu; Xiaoyong Zhang
Journal:  J Clin Transl Hepatol       Date:  2020-12-21

6.  The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell lines.

Authors:  Ruo-Chan Chen; Pan-Pan Yi; Rong-Rong Zhou; Mei-Fang Xiao; Ze-Bing Huang; Dao-Lin Tang; Yan Huang; Xue-Gong Fan
Journal:  Mol Cell Biochem       Date:  2014-02-09       Impact factor: 3.396

7.  MicroRNA-98-5p Inhibits Tumorigenesis of Hepatitis B Virus-Related Hepatocellular Carcinoma by Targeting NF-κB-Inducing Kinase.

Authors:  Xiukun Fei; Peipei Zhang; Yu Pan; Yuanyuan Liu
Journal:  Yonsei Med J       Date:  2020-06       Impact factor: 2.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.